The enhanced aqueous extracts of processed AMR (PAMR) demonstrate improved efficacy in treating FD, indicating that this pharmaceutical technology enhances the anti-inflammatory trend and promotes gastric motility by modulating DRD2, SCF, and c-kit. The gene discussed is DRD2; the disease is Fabry disease.